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EVALUATION AND INFECTION THERAPY)
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OBJECTIVES: PROVE-it is the ﬁrst trial comparing an intensive
lipid-lowering treatment with 80mg Atorvastatin vs. 40mg
Pravastatin in acute coronary syndromes (ACS) with a 2-year
follow-up. There were signiﬁcantly less morbimortality with 
80mg atorvastatin vs. 40mg pravastatin: 22.4% vs. 26.3% (p =
0.005). The objective of this economic evaluation is to estimate
the incremental cost-effectiveness of atorvastatin vs. pravastatin
with Spanish costs based on PROVE-IT. METHODS: Cost-
effectiveness analysis was performed under the perspective of the
Spanish health system, projected in the long-term by modelizing
with a decision tree, estimating average life expectancy by the
Framingham cohort. Only drug acquisition costs and direct cots
were considered. Costs were expressed in 2005€. Effectiveness
was measured as primary events avoided (all cause mortality,
AMI, unstable angina, revascularization and stroke) and life
years gained (LYG). Mean cost per patient and incremental cost
effectiveness ratio were calculated as cost per event avoided and
cost per LYG. A univariate sensitivity analysis was performed for
different acute events costs. RESULTS: Mean cost expected per
patient during the 2 years of follow-up was €3180 for atorvas-
tatin and €3210 for pravastatin. Incremental saving of atorvas-
tatin vs. pravastatin was €30 per patient, because the saving for
events avoided by atorvastatin overweighs its higher acquisition
cost. Beneﬁt of atorvastatin vs. pravastatin was 0.103 life years
per patient. Incremental cost-effectiveness of atorvastatin vs.
pravastatin was €543 per event avoided and €296 per LYG.
These results were robust to the sensitivity analysis. CONCLU-
SIONS: Under the perspective of the Spanish health system,
intensive treatment with 80mg atorvastatin is a more effective
treatment and is less costly than 40mg pravastatin, in acute coro-
nary syndromes, according to a model based in the PROVE-it
trial. Therefore treatment with atorvastatin 80mg is a dominant
or cost-saving strategy, allowing other Spanish resources to be
used on other treatments.
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OBJECTIVE: The objective was to determine the short- and
long-term health care costs and cost-effectiveness associated with
atorvastatin 80mg (atv) after the occurrence of an ACS in
Belgium, through the customisation of two models. METHODS:
The models are based on studies in ACS patients: the MIRACL
study, reporting the short-term effect (16 weeks) of atv versus
placebo and the PROVE-IT study, comparing the effect of atv
versus pravastatin 40mg (pra) for a mean follow-up period of
24 months. For each event causing a rehospitalisation, a corre-
sponding APR-DRG code and cost was identiﬁed. The cost of
treatment was calculated by multiplying the daily cost of atv
(€2.10)/pra (€1.53) by the mean duration of exposure. The hos-
pitalisation cost in each cohort was estimated by multiplying the
probability of events by the corresponding cost. The cost-
effectiveness was expressed as the incremental cost/event
avoided. For PROVE-IT the incremental costs/LYG was obtained
by using life expectancy estimates from the Framingham cohort.
A third payers’ perspective was chosen (RIZIV/INAMI). A mul-
tivariate sensitivity analysis was performed for both models.
RESULTS: The total cost/patient (hospitalisation + treatment)
was €2511.29 (atv) vs. €2480.79 (placebo) in MIRACL and
€3308.73 (atv) vs. €3285.25 (pra) in PROVE-IT. The incremen-
tal cost/patient was €9.60/month for the MIRACL cohort and
€1/month for the PROVE-it cohort, associated with an absolute
risk reduction for re-hospitalisation of 3.8% and 5.6% respec-
tively. The incremental cost/event avoided was €795.64 (C.I.: 
-€4047.32–€38,277.14) and €419 (C.I.: -€2,688–€8,725), for
MIRACL and PROVE-IT, respectively. The incremental cost/life
year gained was €229 (C.I.: -€3743, €5003) and €764 (C.I. 
-€35,604, €30,184), when death from any cause and cardiovas-
cular death only, respectively, was calculated. CONCLUSION:
In Belgium, the clinical beneﬁts of intensive short-and long-term
atorvastatin treatment were associated with a favourable health
economical outcome, resulting in a small incremental cost for
better outcomes.
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OBJECTIVE: The aim of this study was to design a pilot study
on pharmacoeconomic evaluation of the acute coronary 
syndromes therapy in the coronary care unit in Slovakia.
METHODS: Literature review, design of criteria needed for
patients selection on pharmacoeconomical analysis according to
CURE study, retrospective “cost—effectiveness” analysis on
acute coronary syndromes therapy. Study was set-in coronary
care unit in internal medicine department of a university hospi-
tal. A main outcome measure was comparison pharmacotherapy
with ESC Guidelines, in hospital costs evaluation. RESULTS: All
patients of the 1st phase of the study with acute coronary syn-
dromes diagnosis without ST-segment elevation (n = 15, age 60
± 16,5 years) were treated following ECS Guidelines during hos-
pitalization (ASA 86.6%; heparin or low molecular weight
heparin 100%; ACE inhibitor 73.5%; beta-blocker 85%;
calcium-channel blocker 93%; lipid-lowering agent 85%, intra-
venous nitrate 100%). Their pre-hospitalization medical history
was hypertension (73.3%), diabetes (40%) and smoking (40%),
myocardial infarction (20%). In-hospital costs were €1515 per
1 patient, including pharmacotherapy €60.5, interventions and
investigations €1320.6 and overhead charges €133. Average
length of stay in the hospital was 8.2 days. Subanalysis of eval-
uation showed higher hospitalization costs in women group
(non-signiﬁcant because of small number of patients). Post-
hospitalization therapy was not observed and evaluated. CON-
CLUSIONS: The analysis showed: 1. Patients with acute 
coronary syndromes diagnosis were treated following ECS
Guidelines in hospital; 2. The most ﬁnancial resources were used
for medical interventions and investigations; 3. The pilot phar-
macoeconomical analysis study of the acute coronary syndromes
showed the need of following studies they can compare using of
various molecules and their effect on post-hospitalization quality
of life.
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